LyGenesis Receives Award from Breakthrough T1D® to Fund a Research Project to Induce Immune Tolerance to Pancreatic Islet Transplantation
PITTSBURGH, June 25, 2026 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing cell therapies for organ regeneration, today announced a research award from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, to...
PITTSBURGH, June 25, 2026 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing cell therapies for organ regeneration, today announced a research award from Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization, to...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.